- Kolon’s cell-based gene therapy fails phase 3 osteoarthritis trialA phase 3 trial of Kolon TissueGene’s cell-based gene therapy has missed its co-primary endpoints. With a second late-stage study scheduled to report data in October, the biotech is holding off on…Fierce Biotech · 8d ago↗ source
- Tempus buys out cancer genomics partner Personalis in $1.5 billion dealTempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.Fierce Biotech · 8d ago↗ source
- Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic medsScribe Therapeutics has put its IPO plans down on paper, showing the genetic medicine company hopes to raise $96 million through its public listing.